| Title |
Non-tumor necrosis factor-based biologic therapies for rheumatoid arthritis: present, future, and insights into pathogenesis
|
|---|---|
| Published in |
Biologics: Targets & Therapy, December 2013
|
| DOI | 10.2147/btt.s35475 |
| Pubmed ID | |
| Authors |
Filipe Seguro Paula, José Delgado Alves |
| Abstract |
The way rheumatoid arthritis is treated has changed dramatically with the introduction of anti-tumor necrosis factor (anti-TNF) biologics. Nevertheless, many patients still have less than adequate control of their disease activity even with these therapeutic regimens, and current knowledge fails to explain all the data already gathered. There is now a wide range of drugs from different classes of biologic disease-modifying anti-rheumatic drugs available (and soon this number will increase significantly), that provides the opportunity to address each patient as a particular case and thereby optimize medical intervention. Currently available biologics for the treatment of rheumatoid arthritis apart from anti-TNF-based therapies are reviewed, along with an analysis of the new insights they provide into the pathogenesis of the disease and a discussion of future prospects in the area. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Practitioners (doctors, other healthcare professionals) | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 48 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 1 | 2% |
| Ireland | 1 | 2% |
| Unknown | 46 | 96% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 10 | 21% |
| Student > Ph. D. Student | 9 | 19% |
| Other | 6 | 13% |
| Researcher | 6 | 13% |
| Student > Master | 4 | 8% |
| Other | 6 | 13% |
| Unknown | 7 | 15% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 18 | 38% |
| Agricultural and Biological Sciences | 8 | 17% |
| Pharmacology, Toxicology and Pharmaceutical Science | 3 | 6% |
| Computer Science | 2 | 4% |
| Immunology and Microbiology | 2 | 4% |
| Other | 8 | 17% |
| Unknown | 7 | 15% |
Attention Score in Context
This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 12 August 2014.
All research outputs
#17,032,385
of 25,806,080 outputs
Outputs from Biologics: Targets & Therapy
#187
of 286 outputs
Outputs of similar age
#201,349
of 323,266 outputs
Outputs of similar age from Biologics: Targets & Therapy
#4
of 7 outputs
Altmetric has tracked 25,806,080 research outputs across all sources so far. This one is in the 31st percentile – i.e., 31% of other outputs scored the same or lower than it.
So far Altmetric has tracked 286 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.2. This one is in the 32nd percentile – i.e., 32% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 323,266 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 35th percentile – i.e., 35% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 7 others from the same source and published within six weeks on either side of this one. This one has scored higher than 3 of them.